SCHEMBL2368992

SCHEMBL2368992

Cc1cccc(CNc2nc(N(CCO)CCO)nc3sc(C)c(Br)c23)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRUNE1 Q86TP1 1/20 0.37
CCNE2 O96020 6/20 0.35
CCNE1 P24864 6/20 0.35
CDK2 P24941 6/20 0.35
SLC29A1 Q99808 7/20 0.33
CACNA2D1 P54289 1/20 0.32
KCNH2 Q12809 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CDK1 P06493 2/20 0.31
CDK5 Q00535 2/20 0.31
PDE5A O76074 2/20 0.31
PDE4D Q08499 2/20 0.31
CCNT1 O60563 1/20 0.31
CCNB1 P14635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368717 0.87 MEN1 (0.45) PRUNE1CCNE2CCNE1CDK2KCNH2
SCHEMBL2368489 0.85 PRKCI (0.41) PRUNE1CCNE2CCNE1CDK2KCNH2
SCHEMBL2368725 0.83 MEN1 (0.38) PRUNE1CCNE2CCNE1CDK2SLC29A1
SCHEMBL2369432 0.82 GAA (0.36) CCNE2CCNE1CDK2CACNA2D1KDM4E
SCHEMBL2368642 0.78 ESR1 (0.47) PRUNE1CCNE2CCNE1CDK2KCNH2
SCHEMBL2368838 0.78 CCNE2 (0.41) CCNE2CCNE1CDK2KDM4EALDH1A1
SCHEMBL2368403 0.76 ESR1 (0.38) PRUNE1CCNE2CCNE1CDK2KDM4E
SCHEMBL2368892 0.74 KCNH2 (0.48) CCNE2CCNE1CDK2KCNH2LMNA
SCHEMBL2368351 0.71 CCNE2 (0.41) CCNE2CCNE1CDK2KDM4EALDH1A1
SCHEMBL2368637 0.71 KCNA5 (0.43) CCNE2CCNE1CDK2KCNH2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 PRUNE1 3231/4885CCNE2 4258/4885CCNE1 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.